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HIV-positive individuals engage in substance use at higher rates than the general 
population and are more likely to also suffer from concurrent psychiatric disorders 
and substance use disorders. Despite this, little is known about the unique clinical 
concerns of HIV-positive individuals entering substance use treatment. This study 
examined the clinical characteristics of clients (N=1712) entering residential 
substance use treatment as a function of self-reported HIV status (8.65% HIV-
positive). Results showed higher levels of concurrent substance use and psychiatric 
disorders for HIV-positive individuals, who were also significantly more likely to 
meet criteria for bipolar disorder and borderline personality disorder. Past diagnoses 
of depression, posttraumatic stress disorder, and social phobia were also significantly 
more common. Study findings indicate a need to provide more intensive care for 
HIV-positive individuals, including resources targeted at concurrent psychiatric 
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List of Tables 
 
Table 1. 
Demographics Variables as a Function of HIV Status 
 
Total N = 1712 
Total 
Sample 
          HIV Status 
HIV-positive HIV-negative 
(N< 148)           (N<1564) 













  Gender (% male) 65.9 55.6 66.8 .005 7.77 
  Race (% African American) 89.3 87.4 89.5 .426 0.64 
  Income (% <$10,000) 79.3 84.1 78.9 .132 2.27 
  Education (% <HS education) 39.2 40.4 39.0 .744 0.11 
  Marital Status (% single) 66.5 64.0 66.7 .495 0.47 
  Employment Status (% unemployed) 75.4 81.8 74.9 .062 3.47 
Treatment and Other Experiences      
  Referral Status (% court mandated)  69.3 68.0 69.4 .719 0.13 
  Inpatient/outpatient treatment for SUDs  72.6 79.5 72.0 .048 3.94 
  Inpatient/outpatient psychiatric treatment  62.4 73.3 61.4 .004 8.37 
  Previous 12-step group attendance  66.1 76.5 65.2 .005 7.84 
  Psychiatric medication (current)  45.2 57.1 44.1 .002 9.26 
  Psychiatric medication (lifetime) 55.1 68.7 53.9 .001 12.1 
  Spent time in jail or prison 92.9 89.9 93.1 .141 2.17 
      
  















Table 2.  
 
Psychiatric Disorders as a Function of HIV Status 
 
Total N = 1712 
 















Any Psychiatric Disorder Current
a 
53.1 65.1 52.1   .001 1.64 (1.16-2.33) 
Any Mood Disorder Current
b
 26.8 34.9 26.1   .033 1.48 (1.03-2.11) 
Bipolar I Disorder  5.6 10.5 5.2  .010 2.14 (1.20, 3.81) 
Major Depressive Disorder Current 20.9 24.8 20.6    .435 1.17 (0.79, 1.74) 
Major Depressive Disorder Past 35.5 44.6 34.7    .020 1.50 (1.07, 2.10) 
Psychotic Symptoms Current 14.3 14.1 14.3 .811 0.94 (0.57, 1.56) 
Psychotic Symptoms Past 19.4 21.2 19.2 .799 0.94 (0.61, 1.47) 
Any Anxiety Disorder Current
c 
21.6 28.4 21.0 .071 1.42 (0.97, 2.07) 
Panic Disorder Current 3.3 4.7 3.2 .552 1.28 (0.57, 2.90) 
Panic Disorder Past 4.9 7.5 4.7 .272 1.45 (0.75, 2.82) 
Social Phobia Current 4.7 7.5 4.4 .096 1.75 (0.91, 3.37) 
Social Phobia Past 4.8 10.3 4.3 .002 2.56 (1.43, 4.58) 
OCD Current 1.9 3.4 1.8 .100 2.26 (0.85, 5.99) 
OCD Past 1.8 2.7 1.7 .252 1.87 (0.64, 5.46) 
PTSD Current 10.3 11.6 10.2 .745 1.10 (0.63, 1.90) 
PTSD Past 17.7 25.4 17.1 .039 1.54 (1.02, 2.32) 
GAD Current 8.5 10.1 8.3   .513 1.20 (0.69, 2.12) 
GAD Past 6.0 9.1 5.8   .591 1.41 (0.40, 4.94) 
Borderline Personality Disorder 13.3 19.3 12.7   .045 1.60 (1.01, 2.52) 
Antisocial Personality Disorder 23.2 24.1 23.1 .391 1.20 (0.79, 1.80) 
 
Analyses that are bolded are significant. 
a. Includes mood disorders, anxiety disorders, psychotic symptoms, borderline personality disorder, 
and antisocial personality disorder. 
b. Includes major depressive disorder, bipolar I, and bipolar II , which was not included alone here 
due to low base rates. 











Table 3.  
 
Prevalence of Participants with Substance Dependence as a Function of HIV Status 
 
 
Total N = 1712 
 













Alcohol Dependence Current 30.6 33.6 30.4 .629 1.09 (0.76, 1.57) 
Alcohol Dependence Past 30.9 38.5 30.3 .099 1.38 (0.94, 2.01) 
Cannabis Dependence Current 10.3 7.0 9.7 .607 0.84 (0.43, 1.65) 
Cannabis Dependence Past 24.9 24.6 25.0 .492 1.16 (0.77, 1.75) 
Cocaine Dependence Current 35.7 55.5 34.0 .001 2.21 (1.56, 3.14) 
Cocaine Dependence Past 37.5 58.9 35.7 .001 2.23 (1.51, 3.30) 
Opioid Dependence Current 18.5 20.5 18.3 .885 1.03 (0.67, 1.58) 
Opioid Dependence Past 20.3 18.2 20.5 .222 0.74 (0.46, 1.20) 
Hallucinogen/PCP Dependence Current 13.5 9.0 13.9 .819 0.82 (0.44, 1.52) 
Hallucinogen/PCP Dependence Past 19.6 12.8 20.2 .098 0.65 (0.39, 1.08) 
Any Current Substance Dependence  72.3 83.8 71.3 .009 1.84 (1.17, 2.90) 
Current SUD / Psychiatric Disorder  42.5 56.1 41.4 .002 1.72 (1.22, 2.42) 
      
 
Analyses that are bolded are significant. 
















Table 4.  
 
Total Number of Disorders as a Function of HIV Status 
 














Total Number of Disorders 2.03 (1.82) 2.46 (1.84) 1.99 (1.81) .002 9.53 
Total Psychiatric Disorders .98 (1.31 1.24 (1.41) .96 (1.30) .013 6.18 
Total Substance Use Disorders 1.04 (.91) 1.22 (.83) 1.03 (.92) .010 6.63 
Total Mood Disorders  .26 (.46) .35 (.51) .25 (.45) .009 6.75 







HIV infection, HIV transmission, and substance use disorders (SUDs) are 
highly associated with each other—substance users are more likely to be infected 
with HIV (Drumright, Patterson, & Strathdee, 2006; Plankey et al., 2007; Schneider, 
Chersich, Neuman, & Parry, 2012) and HIV-positive individuals use substances at 
higher rates than the general population (Bing et al., 2001). HIV-positive substance 
users show increased rates of medical, psychiatric, and substance use disorders, which 
are associated with poorer HIV medication adherence and higher morbidity and 
mortality compared to HIV-positive peers who do not use substances (Altice, 
Kamarulzaman, Soriano, Schechter, & Friedland, 2010).  
In particular, co-occurring psychiatric disorders are highly prevalent among 
HIV-positive substance users (Bing et al., 2001; Turrina et al., 2001). The 
combination of psychiatric disorders and substance use among individuals living with 
HIV is associated with greater psychopathology and worse prognosis compared to the 
effects of a psychiatric disorder or substance use disorder alone (Nnadi et al., 2002). 
People who are triply diagnosed with HIV, a substance use disorder, and a psychiatric 
disorder are thought to be overrepresented in the patient populations of many 
treatment settings due to the severity and chronic nature of their symptomatology 
(Gupta, Kumar, & Garg, 2013). Several studies with HIV samples have shown 
substance use disorders at rates of 32-44% (Burnam et al., 2001; Stall & Leigh, 1994; 
Whetten et al., 2005), psychiatric disorders among 10-60% (Lyketsos et al., 1994; 
Whetten et al., 2005), and concurrent diagnoses of psychiatric and substance use 




Leigh, 1994; Whetten et al., 2005). These findings are concerning given research that 
has demonstrated psychiatric disorders can interfere with effective substance use 
treatment among HIV-positive and HIV-negative individuals alike. For example, 
substance users with co-occurring psychopathology are more likely to drop out of 
treatment, to experience substance use relapse, and to be readmitted for additional 
treatment in the future (Alterman, McLellan, & Shifman, 1993; Brown et al., 1998; 
Greenfield et al., 1998; Hasin et al., 2002; Moos, Mertens, & Brenna, 1994). 
Therefore, to provide the best clinical care to HIV-positive substance users, it is 
important to determine what specific substance use and psychiatric disorders affect 
this population. 
 Despite the clear link between HIV infection and substance use disorders, 
relatively little is known about the unique mental health characteristics of HIV-
positive individuals engaged in substance use treatment. In one study, Turrina and 
colleagues (2001) compared rates of depression among injection drug users who were 
HIV-positive and HIV-negative, and found that a major depression diagnosis was 
roughly twice as common for HIV-positive injection drug users (36.2% vs. 15.7%). 
However, this work was limited in its scope as it focused exclusively on depression 
and select personality factors, and only included substance users who injected drugs. 
It also recruited its HIV-negative sample from a separate treatment site from the HIV-
positive group. A multitude of studies have shown that non-injection drug use is 
associated with HIV infection, transmission, and clinical course (see Van Tieu & 
Koblin, 2009), which points to the importance of including non-injection drug users 




literature on HIV-positive substance users has focused on the impact that a mental 
health or substance use disorder has on adherence to highly active antiretroviral 
therapy (HAART; Chander, Himelhoch, & Moore, 2006). While HAART medication 
adherence is undoubtedly an important outcome, the focus on adherence has meant 
less attention has been paid to factors that may relate to successful substance use 
treatment outcomes. No study has examined rates of psychopathology among HIV-
positive individuals in substance use treatment using an HIV-negative comparison 
group. 
 To better characterize the unique treatment needs of HIV-positive substance 
users, the current study utilized data from HIV-positive and HIV-negative individuals 
entering a substance use treatment center in Washington, DC. We examined rates of 
substance dependence, psychiatric disorders, and their co-occurrence as a function of 
HIV status using the Structured Clinical Interview for the DSM-IV and the 
Diagnostic Interview for Personality Disorders. In comparing psychopathology across 
these two groups, we utilized a count total of the number of current disorders for each 
participant. Next, we focused on rates of disorders in mental health categories 
including substance use disorders, mood disorders, anxiety disorders, psychiatric 
disorders, and co-occurring substance use disorders and psychiatric disorders. Finally, 
we narrowed comparison analyses to specific individual DSM-IV diagnoses with the 
goal of painting a contrasting picture of the clinical needs of substance users who are 
HIV-positive versus HIV-negative. 
 Based on previous literature, a number of hypotheses were made regarding 




substance use treatment were hypothesized to meet for a greater number of DSM-IV 
diagnoses overall if they were HIV-positive. In terms of individual psychiatric 
disorders, we expected elevated rates of Major Depressive Disorder (MDD) and 
Posttraumatic Stress Disorder (PTSD), as both are more highly prevalent among 
individuals living with HIV (Katz & Nevid, 2005; Komiti et al., 2003; Martinez, 
Israelski, Walker, & Koopman, 2002; Safren, Gershuny, & Hendriksen, 2003). MDD 
and PTSD are also known to co-occur with substance use disorders (Swendsen & 
Merikangas, 2000). We also hypothesized that HIV-positive individuals would show 
higher rates of disorders across categories including substance use disorders, mood 
disorders, anxiety disorders, general psychiatric disorders, and concurrent substance 
use and psychiatric disorders. Finally, in addition to predicting higher rates of 
substance dependence overall, we made hypotheses for specific substances. HIV-
positive individuals were expected to endorse higher rates of current and past opioid 
and cocaine dependence. Historically, injection of heroin has been associated with 
HIV epidemics through the sharing of needles and works as well as through related 
sexual risk behaviors (Battjes, Pickens, & Amsel, 1991; Centers for Disease Control, 
1990). Transmission of HIV has also been linked to risky sexual behavior, including 
sex exchange, in the context of crack cocaine use (Edlin et al., 1994). Thus, HIV-
positive individuals engaged in substance use treatment may present with elevated 
rates of dependence on heroin and crack cocaine compared to their HIV-negative 
peers. In summary, the current study aimed to test the hypothesis that HIV-positive 









Participants (N=1712) were sequential admissions to a residential substance use 
treatment center in Northeast Washington D.C. from March 2009 through June 2014. 
The mean age of the sample was 42.8 years old (SD 10.9). The majority of the sample 
identified as African American (89.3%), followed by Hispanic (4.3%), Caucasian 
(3.5%), American Indian/Alaskan Native (.4%), Asian (.3%), and individuals 
identifying as “other” (2.1%). Participants were recruited during their first week of 
residential treatment after completing detoxification and submitting a negative urine 
screen. The length of treatment contracts at this facility typically ranges from 28 to 
180 days and depends on the agency providing funding for the client. More than 30% 
of clients in this setting enter treatment voluntarily through the Addiction Prevention 
and Recovery Administration (APRA). The remainder are court-mandated to attend 
the program by criminal justice institutions: Court Services and Offender Supervision 
Agency (CSOSA) and Pretrial Services Agency (PSA). Treatment programming 
includes a variety of groups from 8 am to 9 pm daily based on the 12-step philosophy, 
as well as small groups that focus on specific client needs, such as Anger 
Management, Grief and Loss, Family Issues and Trauma, and Dual Diagnosis. Clients 
are only permitted to leave the facility for approved scheduled appointments with 





Recruitment and consent 
During their first week of treatment, all participants in this study received a 
diagnostic assessment administered by University of Maryland doctoral level 
graduate students and senior research staff as a part of the treatment center’s intake 
process. In addition to providing diagnostic information to the clinical treatment staff 
of the center, the assessment was also used to gather data for the current study. Upon 
finishing the interview, clients were invited to be involved with research and 
informed consent was obtained. In order to limit coercion, counselors were unaware 
of whether clients agreed to participate in research. The current data presented here 
are only from individuals who consented to participate in research (< 5% refused 
research participation). The University of Maryland Institutional Review Board 
reviewed and approved all aspects of the study protocol. 
Procedures 
All interviewers were extensively trained and comprehensively supervised to 
ensure the accuracy of diagnoses. Trainees first watched the full video protocol for 
the Structured Clinical Interview for the DSM-IV (SCID-IV; First, Spitzer, Gibbon, 
& Williams, 1995). After reviewing the protocol, trainees next conducted two mock 
interviews using the SCID-IV and the Diagnostic Interview for Personality Disorders 
(DIPD; Zanarini, Frankenburg, Chauncey, Gunderson, 1987). The final stages of the 
training included observing two full diagnostic assessments performed by 
experienced interviewers at the treatment center, completing a final certification 




observed by supervisors at the treatment center. Once training was completed, all 
interviewers participated in an ongoing weekly supervision meeting led by a clinical 
psychologist. Any clinical questions regarding specific clients or diagnoses were 
addressed through group discussion and feedback. 
Measurements 
Demographic Variables and HIV Status. Participants self-reported their HIV status, 
gender, age, race, marital status, income, education, previous treatment for substance 
use or psychiatric disorders, incarceration history, and drug use frequency. 
Participants’ HIV status was corroborated with records from the medical staff at the 
treatment center. 
Diagnostic assessments. The Structured Clinical Interview for the DSM-IV (SCID-
IV; First, Spitzer, Gibbon, & Williams, 1995) was used to assess the following Axis I 
disorders:  major depressive disorder, bipolar I disorder, panic disorder, social phobia, 
obsessive compulsive disorder, posttraumatic stress disorder, generalized anxiety 
disorder, and drug dependencies. Participants were also assessed for the presence or 
absence of psychotic symptoms using a screener included in the SCID-IV. Substance 
abuse was not assessed given the severity of the drug use among this inpatient 
sample. Participants were diagnosed with current substance dependence if they 
endorsed three or more dependence symptoms for at least one month during the last 
year. Past substance dependence was diagnosed when participants met this threshold 
for at least a one month period outside of the last 12 months (but was only assessed 
for any drugs for which the client already had not already met criteria for current 




were substance-induced or the result of other underlying causes, interviewers 
established a comprehensive symptom timeline with each participant, ensuring that 
diagnoses were made only in cases when symptoms were not the direct result of the 
pharmacological effects of substance use or a general medical condition. We also 
assessed participants for antisocial personality disorder (ASPD) using the SCID-IV 
and borderline personality disorder (BPD) using the DIPD. Proponents of the DIPD 
have argued that it is a more comprehensive and precise measure of BPD than the 
SCID-IV (Zanarini, Frankenburg, Chauncey, & Gunderson, 1987). These Axis II 
disorders were chosen because previous work has shown that they are particularly 
prevalent among substance users (Kokkevi, Stefanis, Anastasopoulou, & Kostogianni, 
1998; Torrens, Gilchrist, & Domingo-Salvany, 2011). 
Analytic strategy 
Data were analyzed using ANOVA’s for continuous variables and chi-square 
tests for categorical variables to examine the significance of group differences by 
HIV status. Odds ratios and effect sizes were calculated for the relevant analyses. 
Variables were created to compare groups for the presence of a diagnosis in disorder 
categories (e.g. mood disorders, anxiety disorders, substance use disorders, and 
psychiatric disorders) as well as the total number of disorders across those categories. 
More detailed explanation of these variables is provided in the tables below. 
Regression analyses with relevant significant demographic differences such as age 
and gender entered as covariates were performed to confirm that significant outcomes 






Demographic and background information 
Of the total 1712 participants in this sample, 8.65% (n=148) identified as 
HIV-positive. HIV-positive and negative participants did not differ significantly by 
race, income, education, or marital status (see Table 1). However, HIV-positive 
participants were older and more likely to be female. A significantly greater 
proportion of HIV-positive individuals had attended previous treatment for substance 
use disorders and for other psychiatric help. They were also more likely to take 
mental health medication both currently and in the past (all p’s < .05; see Table 1). 
The majority of both groups had spent time in jail or prison and were court-mandated 
to attend treatment at the center, with no significant differences by HIV status on 
these variables. 
 
Psychiatric disorder diagnoses 
HIV-positive participants were significantly more likely to currently meet 
diagnostic criteria for any Axis I or II psychiatric disorder than their HIV-negative 
counterparts (65.1% vs. 52.1%, p = .001; see Table 2). Overall, they were 
significantly more likely to have a current mood disorder (34.9% vs. 26.1%, p = 
.033), Bipolar I Disorder (10.5% vs. 5.2%, p = .010), or borderline personality 
disorder (BPD; 19.3% vs. 12.7%, p = .045). In terms of past psychiatric diagnoses, 
only 34.7% of HIV-negative participants met diagnostic criteria for major depressive 
disorder (MDD), as compared to 44.6% of HIV-positive participants. Past diagnoses 




more common in the HIV-positive group. Rates of antisocial personality disorder 
(ASPD) and other psychiatric disorders did not differ as a function of HIV status (all 
p’s > .05). 
 
Substance dependence diagnoses 
In the overall sample, 72.3% of individuals met diagnostic criteria for a 
current substance dependence diagnosis. Rates of dependence on specific substances 
differed as a function of HIV status (see Table 3). As expected, HIV-positive 
participants were significantly more likely to meet diagnostic criteria for cocaine 
dependence (both current and past) in comparison to HIV-negative individuals 
(55.5% vs. 34% for current cocaine dependence, p = .001). Contrary to our 
hypotheses, there was not a corresponding higher rate of opioid dependence for the 
HIV-positive group; the rate of current and past opioid dependence was roughly 20% 
across both groups. Dependence rates across other substances did not differ as a 
function of HIV status. In line with predictions, HIV-positive participants did show 
higher levels of concurrent substance use and psychiatric disorders (56.1% vs. 41.4%, 
p = .002). Coming to treatment with a current substance dependence diagnosis was 
also more likely, with 83.8% of HIV-positive participants meeting criteria for at least 
one drug versus 71.3% of the comparison HIV-negative group. 
 
Total number of disorders by HIV status 
We also examined the total number of disorders each participant met criteria 
for in a number of diagnostic categories. Here, the average total number of disorders 




further, members of the HIV group met for a higher number of psychiatric disorders, 
substance use disorders, and mood disorders. The number of anxiety disorders also 




This study aimed to compare individuals entering inpatient substance use 
treatment across HIV status, to identify any differences in clinical profiles between 
the two groups. HIV-positive individuals with substance use problems represent an 
important population to examine in depth, as substance use and mental health 
problems are associated with worse HIV medication adherence and higher mortality 
rates (Altice et al., 2010). This is particularly concerning given half of clients with 
concurrent psychiatric disorders who attend substance use treatment report that they 
received no mental health treatment during their substance use care (Watkins et. al., 
2004). Moreover, less than half of substance use treatment programs conduct mental 
health screenings at intake (42%; SAMHSA, 2009). This context makes gathering 
more information on the clinical concerns unique to HIV-positive substance use 
treatment clients even more relevant to ensuring their long-term physical and mental 
health. To our knowledge, this paper marks the first effort to examine rates of 
psychiatric and substance use disorders among HIV-positive clients in an inpatient 
substance use setting compared to their HIV-negative peers. 
There were significant differences in the presence of substance dependence 




sample, HIV-positive clients were more likely to present with a history of major 
depressive disorder, posttraumatic stress disorder, and social phobia, as well as 
current diagnoses of bipolar disorder and borderline personality disorder. The 
increased likelihood of a history of MDD and PTSD are in line with expectations 
given similar findings from the extant literature for HIV-positive individuals in a 
variety of samples and settings (Katz & Nevid, 2005; Komiti et al., 2003; Martinez, 
Israelski, Walker, & Koopman, 2002; Safren, Gershuny, & Hendriksen, 2003). For 
example, Turrina and colleagues (2001) showed that a current major depression 
diagnosis was more than twice as common for injection drug users who were HIV-
positive (36% vs. 16%). Our results differed in that there was not a significant 
difference in current MDD by HIV status, and this may be a function of the relatively 
high levels of current depression in the overall sample and HIV-negative group (21% 
overall and for HIV-negative vs. 25% among HIV-positive). Still, nearly half of this 
study’s HIV-positive clients met criteria for a past depression diagnosis, meaning 
they were significantly more likely to have experienced prior episodes of depression 
than their HIV-negative counterparts (45% vs. 35%). Because individuals with a 
history of depression are at increased risk of future episodes, preventative mental 
health resources and psychoeducation for this group are likely to have protective 
effects and lead to better treatment outcomes across the board. Similar to depression, 
the overall number of clients presenting with a current PTSD diagnosis in our sample 
was relatively large for a setting not focused specifically on trauma or mental health 
(roughly 10% of the HIV-negative group met current criteria vs. 12% of HIV-positive 




violence, and other traumatic events at much higher rates than the general population. 
HIV-positive individuals were more likely to have experienced a traumatic event and 
to meet criteria for a past diagnosis of PTSD (25% among HIV-positive vs. 17% 
HIV-negative). Clients also evidenced a greater history of social phobia, which was 
not among the clinical characteristics initially predicted to differ between groups. 
More work is needed to explore this association, but one relevant factor may be the 
fear of disclosure of HIV status in social situations. 
Relatively few studies have examined the potential association of chronic 
mental health conditions such as bipolar disorder and personality disorders with HIV 
infection. The presence of Axis II diagnoses among individuals who are currently 
negative but at-risk for HIV infection means they are more likely to contract HIV in 
the future (Jacobsberg et al., 1995), while other studies have established a relatively 
high proportion of individuals living with HIV have concurrent personality disorders 
(James et al., 1991; Pace et al., 1990; Perkins et al., 1993). Borderline personality 
disorder and antisocial personality disorder in particular have been associated with 
HIV infection, yet these studies have been limited by methodological issues and were 
not focused on substance using samples. Nevertheless, our results showing elevated 
rates of bipolar disorder and borderline personality disorder in the HIV-positive group 
fits with past work, which highlights impulsivity a common factor underlying HIV-
risk behaviors as well as BPD and bipolar disorder. Antisocial personality disorder 
was diagnosed in roughly one in five individuals in both groups, and may not have 




involvement among our sample. Approximately 90% of participants reported prior 
incarceration in jail or prison, for an average of 10 years total in both groups. 
In line with expectations regarding substance use, current and past cocaine 
dependence diagnoses were more prevalent among HIV-positive clients in this 
treatment setting. Contrary to hypotheses, opioid dependence was not associated with 
HIV status. This may be due to regional differences in substance use characteristics or 
the fact that new HIV infection attributable to injection drug use (8%) is quite low 
compared to that for sexual contact including that which occurs in the context of sex 
exchange for drugs (88%; CDC, 2012). 
In addition to distinguishing levels of specific disorders, the current study 
found that HIV-positive clients met for a greater number of disorders overall, 
especially substance use and mood disorders. These clients were also overrepresented 
in larger diagnostic categories, and as such, were also more likely than their HIV-
negative peers to present with concurrent substance use and psychiatric disorders at 
treatment entry. The impact of increased rates of disorders and concurrent diagnoses 
on treatment outcomes for this sample is not known, however previous work suggests 
the potential for a detrimental influence 
 Although data from the current study provide a unique clinical snapshot of 
HIV-positive substance users entering in residential treatment, these results should be 
interpreted in the context of the work’s limitations. First, the lack of information on 
when individuals contracted HIV meant we were unable to link substance use and 
mental health problems to HIV casually in either direction. Future retrospective work 




study with individuals at risk of HIV infection, substance use disorders, and mental 
health problems will be necessary to begin to disentangle these complex associations.  
Similarly, data on treatment outcomes such as dropout and relapse were not 
collected for the majority of the participants in our sample. Extant literature suggests 
that because the HIV-positive individuals from this sample evidenced higher 
psychopathology overall, and concurrent SUD and psychiatric disorders in particular, 
that they are more likely to experience negative treatment outcomes. This dataset did 
not allow us to test that hypothesis. Another potential limitation is that we chose to 
rely on participants’ self-report of their HIV status with corroboration from medical 
information at the treatment center. We elected not to perform HIV tests to verify 
HIV status, because HIV testing is not a part of the routine intake process for this and 
many other substance use treatment centers. Our goal was to model what information 
is typically available to clinicians when their clients come to treatment, and regular 
HIV tests are fairly routine among our sample. Indeed, a recently completed research 
study (n=263) at this treatment center revealed that 100% of clients had been tested 
for HIV in their lifetime, and most had been tested within the past year either in jail, 
through a mobile testing van, or with a health care provider. Finally, while overall we 
see the setting of this study as a strength, the urban treatment center associated with 
low-income substance users may limit the generalizability of these findings. 
 Despite its limitations, this study has important clinical implications and 
highlights the importance of considering HIV status in the assessment and treatment 
of clients entering residential substance use programs. Because HIV-positive 




important for each client’s HIV status to be considered by referral agencies and 
treatment providers in planning care and resources, especially in cases when there are 
limited or no resources to conduct diagnostic assessments. This work suggests 
clinicians may need to provide more intensive care for HIV-positive individuals, 
including resources targeted at concurrent psychiatric problems, to ensure positive 
treatment outcomes following residential discharge. 
 In conclusion, we believe that this study is the most rigorous comparison of 
the clinical characteristics of residential substance users as a function of HIV status to 
date. This work opens the door to future research to attempt to reproduce these 
findings in other settings while examining the relation to treatment outcomes.  
Further, extensions of this work may identify potential mechanisms underlying the 
relation between HIV infection and psychopathology among substance users, as well 















Alterman, A. I., McLellan, A. T., & Shifman, R. B. (1993). Do substance abuse 
patients with more psychopathology receive more treatment? The Journal of 
Nervous and Mental Disease, 181(9), 576-582. 
Altice, F. L., Kamarulzaman, A., Soriano, V. V., Schechter, M., & Friedland, G. H. 
(2010). Treatment of medical, psychiatric, and substance-use comorbidities in 
people infected with HIV who use drugs. The Lancet, 376(9738), 367-387. 
Bing, E. G., Burnam, M. A., Longshore, D., Fleishman, J. A., Sherbourne, C. D., 
London, A. S., ... & Shapiro, M. (2001). Psychiatric disorders and drug use 
among human immunodeficiency virus–infected adults in the United States. 
Archives of general psychiatry, 58(8), 721-728. 
Brown, R. A., Monti, P. M., Myers, M. G., Martin, R. A., Rivinus, T., Dubreuil, M. 
E., & Rohsenow, D. J. (1998). Depression among cocaine abusers in 
treatment: relation to cocaine and alcohol use and treatment 
outcome. Depression, 155(2). 
Burnam, M. A., Bing, E. G., Morton, S. C., Sherbourne, C., Fleishman, J. A., London, 
A. S., ... & Shapiro, M. F. (2001). Use of mental health and substance abuse 
treatment services among adults with HIV in the United States. Archives of 
General Psychiatry, 58(8), 729-736. 
Centers for Disease Control (CDC), 1990. Risk behaviors for HIV transmission 
among intravenous-drug users not in drug treatment--United States, 1987-




Centers for Disease Control (CDC), 2012. Estimated HIV incidence among adults 
and adolescents in the United States, 2007–2010. HIV Surveillance 
Supplemental Report 2012, 17(4). 
Chander, G., Himelhoch, S., & Moore, R. D. (2006). Substance abuse and psychiatric 
disorders in HIV-positive patients. Drugs, 66(6), 769-789. 
Dew, M. A., Becker, J. T., Sanchez, J., Caldararo, R., Lopez, O. L., Wess, J., ... & 
Banks, G. (1997). Prevalence and predictors of depressive, anxiety and 
substance use disorders in HIV-infected and uninfected men: a longitudinal 
evaluation. Psychological Medicine, 27(2), 395-409. 
Drumright, L. N., Patterson, T. L., & Strathdee, S. A. (2006). Club drugs as causal 
risk factors for HIV acquisition among men who have sex with men: a 
review. Substance use & misuse, 41(10-12), 1551-1601. 
Edlin, B. R., Irwin, K. L., Faruque, S., McCoy, C. B., Word, C., Serrano, Y., ... & 
Holmberg, S. D. (1994). Intersecting epidemics--crack cocaine use and HIV 
infection among inner-city young adults. New England Journal of 
Medicine,331(21), 1422-1427. 
Greenfield, S. F., Weiss, R. D., Muenz, L. R., Vagge, L. M., Kelly, J. F., Bello, L. R., 
& Michael, J. (1998). The effect of depression on return to drinking: a 
prospective study. Archives of General Psychiatry, 55(3), 259-265. 
Gupta, M., Kumar, K., & Garg, P. D. (2013). Dual diagnosis vs. triple diagnosis in 
HIV: A comparative study to evaluate the differences in psychopathology and 





Hasin, D., Liu, X., Nunes, E., McCloud, S., Samet, S., & Endicott, J. (2002). Effects 
of major depression on remission and relapse of substance 
dependence. Archives of General Psychiatry, 59(4), 375-380. 
Jacobsberg, L., Frances, A., & Perry, S. (1995). Axis II diagnoses among volunteers 
for HIV testing and counseling. The American Journal of Psychiatry, 152(8), 
1222. 
James, M. E., Rubin, C. P., & Willis, S. E. (1991). Drug abuse and psychiatric 
findings in HIV-seropositive pregnant patients. General Hospital 
Psychiatry, 13(1), 4-8. 
Katz, S., & Nevid, J. S. (2005). Risk factors associated with posttraumatic stress 
disorder symptomatology in HIV-infected women. AIDS Patient Care & 
STDs, 19(2), 110-120. 
Kokkevi, A., Stefanis, N., Anastasopoulou, E., & Kostogianni, C. (1998). Personality 
disorders in drug abusers: prevalence and their association with AXIS I 
disorders as predictors of treatment retention. Addictive Behaviors, 23(6), 841-
853. 
Komiti, A., Judd, F., Grech, P., Mijch, A., Hoy, J., Williams, B., ... & Lloyd, J. H. 
(2003). Depression in people living with HIV/AIDS attending primary care 
and outpatient clinics. Australian and New Zealand Journal of 
Psychiatry, 37(1), 70-77. 
Lyketsos, C. G., Hanson, A., Fishman, M., McHugh, P. R., & Treisman, G. J. (1994). 




infection: the need for a psychiatric presence. The International Journal of 
Psychiatry in Medicine, 24(2), 103-113. 
Maj, M., Janssen, R., Starace, F., Zaudig, M., Satz, P., Sughondhabirom, B., ... & 
Sartorius, N. (1994). WHO neuropsychiatric AIDS study, cross-sectional 
phase I: study design and psychiatric findings. Archives of General 
Psychiatry, 51(1), 39-49. 
Martinez, A., Israelski, D., Walker, C., & Koopman, C. (2002). Posttraumatic stress 
disorder in women attending human immunodeficiency virus outpatient 
clinics. AIDS patient care and STDs, 16(6), 283-291. 
Moos, R. H., Mertens, J. R., & Brennan, P. L. (1994). Rates and predictors of four-
year readmission among late-middle-aged and older substance abuse 
patients. Journal of Studies on Alcohol and Drugs, 55(5), 561-570. 
Nnadi, C. U., Better, W., Tate, K., Herning, R. I., & Cadet, J. L. (2002). Contribution 
of substance abuse and HIV infection to psychiatric distress in an inner-city 
African-American population. Journal of the National Medical 
Association, 94(5), 336. 
Pace, J., Brown, G. R., Rundell, J. R., Paolucci, S., Drexler, K., & McManis, S. 
(1990). Prevalence of psychiatric disorders in a mandatory screening program 
for infection with human immunodeficiency virus: A pilot study. Military 
medicine. 
Perkins, D. O., Davidson, E. J., Leserman, J., Liao, D., & Evans, D. L. (1993). 




implications for clinical care. The American Journal of Psychiatry, 150(2), 
309. 
Plankey, M. W., Ostrow, D. G., Stall, R., Cox, C., Li, X., Peck, J. A., & Jacobson, L. 
P. (2007). The relationship between methamphetamine and popper use and 
risk of HIV seroconversion in the multicenter AIDS cohort study. Journal of 
acquired immune deficiency syndromes (1999), 45(1), 85. 
Safren, S. A., Gershuny, B. S., & Hendriksen, E. (2003). Symptoms of posttraumatic 
stress and death anxiety in persons with HIV and medication adherence 
difficulties. AIDS Patient Care and STDs, 17(12), 657-664. 
 
 
Schneider, M., Chersich, M., Neuman, M., & Parry, C. (2012). Alcohol consumption 
and HIV/AIDS: the neglected interface. Addiction, 107(8), 1369-1371. 
Stall, R., & Leigh, B. (1994). Understanding the relationship between drug or alcohol 
use and high risk sexual activity for HIV transmission: where do we go from 
here? Addiction, 89(2), 131-134. 
Swendsen, J. D., & Merikangas, K. R. (2000). The comorbidity of depression and 
substance use disorders. Clinical psychology review, 20(2), 173-189. 
Torrens, M., Gilchrist, G., & Domingo-Salvany, A. (2011). Psychiatric comorbidity 
in illicit drug users: substance-induced versus independent disorders. Drug 
and Alcohol Dependence, 113(2), 147-156. 
Van Tieu, H., & Koblin, B. A. (2009). HIV, alcohol, and noninjection drug 




Watkins, K. E., Hunter, S. B., Wenzel, S. L., Tu, W., Paddock, S. M., Griffin, A., & 
Ebener, P. (2004). Prevalence and characteristics of clients with co‐occurring 
disorders in outpatient substance abuse treatment. American Journal of Drug 
and Alcohol Abuse, 30(4), 749-764. 
Whetten, K., Reif, S. S., Napravnik, S., Swartz, M. S., Thielman, N. M., Eron Jr, J. J., 
... & Soto, T. (2005). Substance abuse and symptoms of mental illness among 
HIV-positive persons in the Southeast. Southern Medical Journal, 98(1), 9-14. 
Zanarini, M. C., Frankenburg, F. R., Chauncey, D. L., & Gunderson, J. G. (1987). 
The Diagnostic Interview for Personality Disorders: interrater and test-retest 
reliability. Comprehensive Psychiatry, 28(6), 467-480 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 23 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 24 
 
 
 
 
 
 
 
 
 
 
